Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy: current status
Lothar Faber1, Dirk Welge, Dieter Fassbender
1Department of Cardiology, Heart and Diabetes Centre North Rhine-Westphalia, University Hospital of the Ruhr University Bochum, D-32545 Bad Oeynhausen, Germany.
Summary
Percutaneous septal ablation offers a safe and effective alternative to myectomy for treating hypertrophic cardiomyopathy symptoms. This minimally invasive procedure shows high success rates in patients with refractory outflow obstruction.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Hypertrophic cardiomyopathy (HCM) is a primary cardiac condition characterized by unexplained left ventricular hypertrophy.
- Outflow obstruction and refractory symptoms significantly impact patient quality of life.
- Surgical myectomy has been the traditional treatment, but carries substantial risks.
Purpose of the Study:
- To review the etiology, natural history, and treatment of hypertrophic cardiomyopathy.
- To highlight percutaneous septal ablation as a key therapeutic option.
- To evaluate the efficacy and safety of septal ablation in managing HCM.
Main Methods:
- Comprehensive literature review on hypertrophic cardiomyopathy.
- Analysis of a personal series of 382 percutaneous septal ablation interventions.
- Discussion of clinical outcomes, including mortality and complication rates.
Main Results:
- Percutaneous septal ablation is an established alternative to myectomy for specific HCM patients.
- The study reported an in-hospital mortality rate of 1.2% and pacemaker implantation rate of 7%.
- Approximately 90% of patients undergoing septal ablation experienced satisfactory clinical results.
Conclusions:
- Percutaneous septal ablation is a viable and effective treatment for drug-refractory, symptomatic hypertrophic cardiomyopathy with outflow obstruction.
- The procedure demonstrates favorable safety and efficacy profiles.
- Septal ablation represents a significant advancement in the interventional management of HCM.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...